Trial · NCT01020968
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01020968, Phase 2, Completed, Vericel Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy. Trials, record NCT01020968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01020968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
- NCT number
- NCT01020968
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 22 participants, actual
- Lead sponsor
- Vericel Corporation
- Conditions
- Dilated Cardiomyopathy
- Interventions
- Ixmyelocel-T, Vehicle Control
- First posted
- 2009-11-26
- Last updated
- 2021-05-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of major adverse cardiac event (MACE) (MACE defined as: cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary edema, acute heart failure, unstable angina and major bleeding) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Left ventricular ejection fraction (LVEF) (As determined by Echo, Cardiac CT and SPECT) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. | |
| Secondary | Change in LV and RV dimensions and in LV volumes (As determined by Echo, Cardiac CT and SPECT) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. | |
| Secondary | Wall Motion Score Index (WMSI) (As determined by Echo, Cardiac CT and SPECT) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. | |
| Secondary | Assessment of myocardial perfusion in ischemic patient cohort, only (As determined by SPECT) | Baseline and Month 3 | |
| Secondary | Exercise tolerance (6 minute walk test) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Heart failure status (As determined by New York Heart Association (NYHA) heart failure status (NYHA) class and Brain Natriuretic Peptide [BNP]) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Angina status (As determined by Canadian Cardiovascular Society (CCS) classification and Troponin I Levels) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Quality of life (As determined by Minnesota Living with Heart Failure Questionnaire [MLHFQ]) | Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 | |
| Secondary | Pulmonary function (As determined by metabolic stress test) | Baseline, Month 6 and Month 12 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25142002 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01020968
GET https://conductscience.org/api/trials/v1/NCT01020968/registered